The potential acquisition of Syqe Medical by Phillip Morris represents a significant strategic move for the tobacco giant, signaling its entry into the flourishing marijuana industry. With an initial investment of $130 million to support Syqe’s FDA approval process, followed by a possible $650 million acquisition, this deal can potentially make Syqe one of the largest cannabis companies globally. Moreover, Syqe’s innovative inhaler, utilizing raw cannabis inflorescence, could secure FDA approval, positioning the company as a trailblazer in the medical cannabis sector.
Legal on paper, restricted in practice. Inside Germany’s cannabis system, where cultivation is allowed but…
The idea may sound strange: a tobacco plant producing compounds like psilocybin or DMT. Sounds…
The term “addiction” gets thrown around quite freely in everyday language—this is nothing new. Who…
Three days before the Trump administration moved medical marijuana to Schedule III, a new YouGov…
On April 23, 2026, the Trump administration officially moved FDA-approved marijuana products and marijuana products…
Here we are in 2026, and a conflict that was supposed to wrap up in…